[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354278-105":3,"doc-detail-354278-en":81,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","efficacy-and-safety-of-immune-checkpoint-inhibitors-in-the-treatment-of-hematologic-malignancies-an-umbrella-review-of-systematic-reviews-and-meta-analyses","Efficacy and Safety of Immune Checkpoint Inhibitors in the Treatment of Hematologic Malignancies - An Umbrella Review of Systematic Reviews and Meta-Analyses","","This umbrella review synthesizes evidence from systematic reviews and meta-analyses assessing the efficacy and safety of immune checkpoint inhibitors (ICIs) in hematologic malignancies. Evidence is pooled across multiple hematologic cancers to clarify therapeutic potential, identify major safety concerns, and support evidence-based guidance for clinical practice and future research. Searches cover PubMed, Embase, Web of Science, and Cochrane up to May 2025, using AMSTAR for quality and GRADE to judge evidence strength.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/efficacy-and-safety-of-immune-checkpoint-inhibitors-in-the-treatment-of-hematologic-malignancies-an-umbrella-review-of-systematic-reviews-and-meta-analyses/354278/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/efficacy-and-safety-of-immune-checkpoint-inhibitors-in-the-treatment-of-hematologic-malignancies-an-umbrella-review-of-systematic-reviews-and-meta-analyses/354278.png","ImageObject",300,407,{"name":42,"@type":43},"Dipper","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-17","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the purpose of this umbrella review?","Question",{"text":63,"@type":64},"It summarizes evidence from systematic reviews and meta-analyses on the efficacy and safety of immune checkpoint inhibitors (ICIs) in hematologic malignancies, clarifying therapeutic potential and key safety issues.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were included studies selected and assessed?",{"text":68,"@type":64},"A comprehensive search was conducted across PubMed, Embase, Web of Science, and the Cochrane Database up to May 2025. Methodological quality was assessed with AMSTAR and evidence quality for outcomes was evaluated using GRADE.",{"name":70,"@type":61,"acceptedAnswer":71},"Which hematologic cancers showed notable efficacy signals for ICIs?",{"text":72,"@type":64},"ICIs demonstrated significant or moderate efficacy signals in multiple myeloma, relapsed/refractory natural killer T-cell lymphoma, relapsed/refractory chronic lymphocytic leukemia, and relapsed/refractory primary mediastinal B-cell lymphoma.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354278,1790176633,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":33,"preview_urls":99},1374404997633,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd",8,"Cancer Medicine  \nREVIEW  OPEN ACCESS   \nEfficacy and Safety of Immune Checkpoint Inhibitors in the Treatment of Hematologic Malignancies: An Umbrella Review of Systematic Reviews and Meta-Analyses  \nZhengyu Yu1  | Zhongwang Wang1  | Li Xie2 | Jing Xu1 | Lang Min1 | Lingfeng Li1 | Ting Niu1,3,4   \n1Department of Hematology, West China Hospital, Sichuan University, Chengdu, China | 2State Key Laboratory of Wildlife Quarantine and Surveillance (Sichuan), Technology Center of Chengdu Customs, Chengdu, China | 3State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, China | 4National Facility for Translational Medicine (Sichuan), west China Hospital, Sichuan University, Chengdu, China  \nCorrespondence: Ting Niu ([niuting@wchscu.cn](niuting@wchscu.cn))  \nReceived: 10 November 2025 | Revised: 26 February 2026 | Accepted: 16 April 2026  \nKeywords: chronic lymphocytic leukemia | immune checkpoint inhibitors | lymphoma | meta-analyses | multiple myeloma | umbrella review  \nABSTRACT  \nBackground: This umbrella review summarizes evidence from systematic reviews and meta-analyses on the efficacy and safety of immune checkpoint inhibitors (ICIs) in hematologic malignancies. To our knowledge, this is the first umbrella review to comprehensively evaluate ICIs across multiple hematologic cancers. The goal is to clarify their therapeutic potential, highlight major safety issues, and provide evidence-based guidance for future clinical and research applications.  \nMethods: A comprehensive search was conducted across PubMed, Embase, Web of Science, and the Cochrane Database of Systematic Reviews up to May 2025. Systematic reviews and meta-analyses investigating ICIs in hematologic malignancies were included. The AMSTAR tool was used to assess methodological quality, and the GRADE system was employed to evaluate the quality of evidence for each outcome.  \nResults: A total of 24 meta-analyses met the inclusion criteria, covering 39 unique interventions. ICIs demonstrated significant efficacy in multiple myeloma (MM), relapsed/refractory natural killer T-cell lymphoma (R/R NKT), relapsed/refractory chronic lymphocytic leukemia (R/R CLL), and relapsed/refractory primary mediastinal B-cell lymphoma (R/R PMBCL) . Pembrolizumab combined with lenalidomide and dexamethasone (PLD) significantly improved overall survival (OS) in MM (HR: 0.51, 95% CI: 0.32 to 0.82, high quality). In R/R NKT, sintilimab and other ICIs showed moderate overall response rates (ORR) with favorable safety profiles. Pembrolizumab also demonstrated moderate efficacy in R/R CLL and R/R PMBCL, with low rates of severe adverse events. However, the studies exhibited significant heterogeneity, and publication bias was detected in certain outcomes, highlighting the need for cautious interpretation.  \nConclusions: ICIs show promising therapeutic potential in several hematologic malignancies, particularly R/R NKT, MM, R/RCLL, and R/R PMBCL. While safety profiles are generally favorable, certain regimens are associated with manageable toxicities. Future research should focus on optimizing combination therapies, refining patient selection criteria, and addressing study heterogeneity to enhance the clinical application of ICIs in hematologic cancers.  \n\n| Zhengyu Yu and Zhongwang Wang authors are contributed equal to this study. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.\u003Cbr>© 2026 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd. |\n\nCancer Medicine, 2026; 15:e71880 1 of 13  \n[https://doi.org/10.1002/cam4.71880](https://doi.org/10.1002/cam4.71880)  \n1 | Introduction  \nHematologic malignancies, encompassing cancers of the blood, bone marrow, and lymphatic ","cbCaigtTGzHlZRSb","https://ap.wps.com/l/cbCaigtTGzHlZRSb","pdf",2296282,13,"English","# Introduction\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What is the purpose of this umbrella review?\",\"answer\":\"It summarizes evidence from systematic reviews and meta-analyses on the efficacy and safety of immune checkpoint inhibitors (ICIs) in hematologic malignancies, clarifying therapeutic potential and key safety issues.\"},{\"question\":\"How were included studies selected and assessed?\",\"answer\":\"A comprehensive search was conducted across PubMed, Embase, Web of Science, and the Cochrane Database up to May 2025. Methodological quality was assessed with AMSTAR and evidence quality for outcomes was evaluated using GRADE.\"},{\"question\":\"Which hematologic cancers showed notable efficacy signals for ICIs?\",\"answer\":\"ICIs demonstrated significant or moderate efficacy signals in multiple myeloma, relapsed/refractory natural killer T-cell lymphoma, relapsed/refractory chronic lymphocytic leukemia, and relapsed/refractory primary mediastinal B-cell lymphoma.\"}]","Efficacy and Safety of Immune Checkpoint Inhibitors in the Treatment of Hematologic Malignancies - An Umbrella Review of Systematic Reviews and Meta-Analyses | PDF",1790109838,33,[100,104,108,112],{"page_no":22,"url":101,"width":102,"height":103},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7ef87f963da4763756a8ad81a70ef7ff.webp",983,1291,{"page_no":26,"url":105,"width":106,"height":107},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/da07284c851caddc31fd3e8dc4a131d2.webp",982,1290,{"page_no":30,"url":109,"width":110,"height":111},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f03d6b9db2d5d6424e8f8cbed02ee66e.webp",981,1289,{"page_no":33,"url":113,"width":114,"height":115},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cabdfa560edc7fd9572207c0bba8189b.webp",980,1287,{"code":4,"msg":82,"data":117},[118,122,126,130,135,140,144,147,152,155,159],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":133,"slug":134},5,"Comic",60,"comic",{"id":136,"doc_module":4,"doc_module_name":25,"category_name":137,"show_sort_weight":138,"slug":139},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":141,"show_sort_weight":142,"slug":143},"Healthcare",40,"healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":145,"slug":146},30,"research-report",{"id":148,"doc_module":4,"doc_module_name":25,"category_name":149,"show_sort_weight":150,"slug":151},9,"Religion & Spirituality",20,"religion-spirituality",{"id":150,"doc_module":4,"doc_module_name":25,"category_name":153,"show_sort_weight":150,"slug":154},"World Cup","world-cup",{"id":156,"doc_module":4,"doc_module_name":25,"category_name":157,"show_sort_weight":156,"slug":158},10,"Lifestyle","lifestyle",{"id":160,"doc_module":4,"doc_module_name":25,"category_name":161,"show_sort_weight":131,"slug":162},19,"General","general"]